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Abstract
Background: In the early stage esophageal cancer, changes in the mucosa are subtle and pass unnoticed in
endoscopic examinations using white light. To increase sensitivity, chromoscopy with Lugol’s solution has been
used. Technological advancements have led to the emergence of virtual methods of endoscopic chromoscopy,
including narrow band imaging (NBI). NBI enhances the relief of the mucosa and the underlying vascular pattern,
providing greater convenience without the risks inherent to the use of vital dye. The purpose of this systematic
review and meta-analysis was to evaluate the ability of NBI to diagnose squamous cell carcinoma of the esophagus
and to compare it to chromoscopy with Lugol’s solution.
Methods: This systematic review included all studies comparing the diagnostic accuracy of NBI and Lugol
chromoendoscopy performed to identify high-grade dysplasia and/or squamous cell carcinoma in the esophagus.
In the meta-analysis, we calculated and demonstrated sensitivity, specificity, and positive and negative likelihood
values in forest plots. We also determined summary receiver operating characteristic (sROC) curves and estimates
of the areas under the curves for both per-patient and per-lesion analysis.
Results: The initial search identified 7079 articles. Of these, 18 studies were included in the systematic review
and 12 were used in the meta-analysis, for a total of 1911 patients. In per-patient and per-lesion analysis, the sensitivity,
specificity, and positive and negative likelihood values for Lugol chromoendoscopy were 92% and 98, 82 and 37%,
5.42 and 1.4, and 0.13 and 0.39, respectively, and for NBI were 88 and 94%, 88 and 65%, 8.32 and 2.62, and 0.16
and 0.12, respectively. There was a statistically significant difference in only specificity values, in which case NBI
was superior to Lugol chromoendoscopy in both analyses. In the per-patient analysis, the area under the sROC
curve for Lugol chromoendoscopy was 0.9559. In the case of NBI, this value was 0.9611; in the per-lesion analysis,
this number was 0.9685 and 0.9587, respectively.
Conclusions: NBI was adequate in evaluating the esophagus in order to diagnose high-grade dysplasia and
squamous cell carcinoma. In the differentiation of those disorders from other esophageal mucosa alterations,
the NBI was shown to be superior than Lugol.
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Background
Esophageal cancer is the eighth most common cancer in
the world (4.9% of all cases). It is the sixth leading cause
of death from cancer, causing 3.2% of deaths [1, 2]. In
2012, the estimated worldwide incidence was 455,800,
with a mortality rate of 400,200 [3, 4]. The two main
histological types are squamous cell carcinoma and
adenocarcinoma [3]. In the areas with the greatest risk,
which span from northern Iran through central Asia to
the central-northern China (known as the “esophageal
cancer belt”), 90% of cases are squamous cell carcinoma;
squamous cell carcinoma is also the principal histo-
logical type worldwide [2].
The importance of individual risk factors in the develop-
ment of squamous cell carcinoma of the esophagus varies
by geographic region [3, 4]. Principal among the risk
factors are consumption of alcohol and tobacco, with the
same “field of cancerization” leading to squamous car-
cinomas of the head, neck, and lungs. Other risk factors
are caustic esophageal stenosis, previous radiation ther-
apy, achalasia, nutritional deficiencies (mainly zinc and
selenium), low fruit and vegetable intake, diets high in
N-nitroso compounds and red meat, diets low in folate,
low socioeconomic status, poor oral hygiene, and inges-
tion of hot liquids [2–4].
Esophageal cancer is a highly aggressive disease, with
a mortality rate of 88% [1]. Overall 5-year survival
between 2002 and 2008 was estimated to be 16.9% [2].
Although survival rates are increasing, they remain low
[2]. This is because most cases are diagnosed when the
disease is in advanced stages [2]. One reason for late
diagnosis is the aggressiveness of the disease: the cancer
quickly invades the submucosa and affects regional
lymph nodes at an early stage, since the lymphatics are
located in the lamina propria of the esophagus, in con-
trast to the rest of the gastrointestinal tract, where they
are located below the muscularis mucosa [4]. Another
important reason is that the early lesions are asymp-
tomatic and changes in the mucosa are subtle, which
easily go unnoticed during endoscopic examination [2, 4].
Distant metastasis to the liver, bones, and lungs is found
in approximately 30% of patients, and in this group, the
average 5-year survival rate is 3.4% [2, 4]. This rate goes
up to 37.8% in patients receiving diagnosis when the
disease is restricted to the esophagus, which occurs in
22% cases [2].
Upper gastrointestinal endoscopy combined with biopsy
is the method of choice for the diagnosis of squamous cell
carcinoma of the esophagus. Technological advancements
have brought an improvement in image quality, making it
easier to identify not only easily visualized advanced
neoplasms but also subtle changes that may correspond
to early stages of the disease. Even with the substantial
improvement in image quality, it is not always easy to
identify these lesions. They may be faint reddish
changes and irregularities in the mucosal relief, which
can easily pass unnoticed in examination with white
light. Esophageal chromoscopy with Lugol’s solution
has been shown to increase the sensitivity of the lesion
detection [5, 6].
In addition to improvements in image quality and
magnification, technology has evolved to allow endos-
copy with chromoscopy using virtual methods. As with
conventional chromoscopy, these methods aim to en-
hance the surface mucosa and the underlying capillary
pattern in the endoscopic examination, but do not re-
quire the application of dye to the esophagus. Principal
among the advantages of virtual methods of endoscopic
chromoscopy is practicality: they involve simply pressing
a button, they do not cause chest discomfort (which is
common when using Lugol’s solution), they bear no risk
of pulmonary aspiration of the dye or allergic reaction,
and they provide a safe assessment of the upper third of
the esophagus. Disadvantages include the high cost of
the device, which decreases accessibility. Ishihara et al.
demonstrated lower sensitivity of narrow band imaging
(NBI) when compared to chromoscopy with Lugol’s
solution among inexperienced endoscopists, with an in-
crease over the course of the study. For experienced
endoscopists, sensitivity levels were consistent between
the two methods [7]. Yokoyama et al. showed that NBI
without magnification is suitable for esophageal assess-
ment when searching for a neoplasm in a high-risk
population, even without high-definition imagery [8].
Virtual chromoscopy methods have been studied and
compared to white light and conventional chromoscopy
in terms of diagnostic accuracy. The purpose of this
systematic review and meta-analysis is to evaluate the
ability of NBI to diagnose squamous cell carcinoma of
the esophagus and to compare the results to those of
chromoscopy with Lugol’s iodine solution. We use
pathological results of biopsies or of dried sections as
the gold standard.
This systematic review is necessary because publica-
tions comparing these two methods have found varying
results. Considering the fact that NBI has the advantage
of not using vital dye, consistent accuracy would be de-
sirable for the use of NBI in clinical practice. We will




A protocol was established and documented prior to the
beginning of the study in order to specify the eligibility
criteria and methods of analysis for the studies included in
this systematic review and meta-analysis. This protocol
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can be accessed at http://www.crd.york.ac.uk/PROSPERO.
Its registration number is CRD42016037008.
Eligibility criteria
Types of studies
This systematic review included all studies from which
data extraction was possible in order to calculate the diag-
nostic accuracy of NBI and Lugol chromoendoscopy in
esophageal assessment for the identification of high-grade
dysplasia and/or squamous cell carcinoma, regardless of
the primary outcome defined by the author. The meta-
analysis used only studies which directly or indirectly
supplied all the data necessary to calculate the sensitivity,
specificity, and positive and negative likelihood values by
patient and/or by lesion, which are analyzed separately in
the current review. No abstracts or data from unpublished
research were accepted. There were no restrictions in
terms of language or date of publication.
Types of participants
There were no restrictions as to sex, age, risk factors, or
previous diagnosis of squamous cell carcinoma of the
esophagus in the study participants. According to the
results, a subgroup analysis was performed if necessary.
Types of intervention
The intervention studied was upper GI endoscopy con-
ducted by experienced endoscopists, in which the esopha-
gus was assessed using NBI and Lugol chromoendoscopy
in order to identify high-grade dysplasia and/or squamous
cell carcinoma of the esophagus. We included studies that
used and did not use magnification findings, and neither
the device diameter (conventional or ultra-thin) nor the
concentration of Lugol’s solution were taken into account.
The gold standard for comparing the two methods was
the results of pathological analysis of the biopsies or
dried sections of the suspicious lesions identified by
both methods.
Types of outcome measures
The primary outcome was the diagnostic accuracy test-
ing for NBI and Lugol chromoendoscopy in identifying
high-grade dysplasia and/or squamous cell carcinoma of
the esophagus.
Sources of information
In order to find articles, searches were conducted in
virtual databases. There were no restrictions as to
language. The databases used in the searches were
PubMed/Medline (all years), Scopus (1988-present),
Cochrane Central Register of Randomised Controlled
Trials/CENTRAL (all years), LILACS (all years), and
Cinahl (all years). The date of the last study in all the
databases was 11/25/2015.
Search
The search strategies that were utilized varied depending
on the database and are specified below:
– PubMed/Medline: (esophagus OR esophageal)
AND (neoplasms OR cancer OR squamous cell
carcinoma OR dysplasia OR dysplastic) AND
(narrow band imaging OR optical imaging OR
nbi OR chromoendoscopy OR lugol OR iodine
OR virtual imaging OR fice OR flexible spectral
imaging color enhancement OR i-scan OR bli OR
blue laser imaging OR endoscopy OR endoscopic)
AND (diagnosis/broad[filter]);
– LILACS and Cochrane/CENTRAL: Esophageal
cancer AND (narrow band imaging OR NBI);
– Scopus: (esophagus OR esophageal) AND
(neoplasms OR cancer OR squamous cell
carcinoma OR dysplasia OR dysplastic) AND
(narrow band imaging OR optical imaging OR
nbi OR chromoendoscopy OR lugol OR iodine
OR virtual imaging OR fice OR flexible spectral
imaging color enhancement OR i-scan OR bli OR
blue laser imaging OR endoscopy OR endoscopic);
– Cinahl: (Esophageal cancer or esophageal Squamous
Cell carcinoma) and (narrow band imaging or nbi).
Study selection
The articles were initially selected after an assessment of
the titles and abstracts in order to assess the relevancy
of the full text. This process was carried out by two in-
dependent reviewers, and differences were resolved after
a discussion and consensus with the participation of all
of the authors of the current review.
The meta-analysis excluded retrospective studies, as well
as studies in which the examinations were performed by
inexperienced endoscopists or when low-grade dysplasia
was considered as the target lesion (true positive), since it
is not possible to distinguish these from high-grade dys-
plasias or squamous cell carcinoma for data collection.
Also excluded were data from studies aimed at evaluating
other outcomes that did not contain at least one patient
evaluated using Lugol chromoendoscopy and NBI.
Data collection process
The data were collected from the absolute numbers that
were directly provided or were inferred through the in-
formation reported in the text. These were placed into
2 × 2 tables and separated for analysis by patient and/or
by lesion according to the data that could be extracted
from each article. These tables separated the true posi-
tives, false positives, true negatives, and false negatives.
The meta-analysis only included studies that provided
all the information necessary to completely fill in the
table for at least one kind of analysis. Those which
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provided all of the data for analysis in the two subgroups
were included in both. The entire process was com-
pleted by two independent authors and revised by all
authors. Differences were resolved after a discussion and
consensus among the authors.
Data items
The criteria considered for the positivity of the methods in
the meta-analysis were the same as those established by the
authors, as long as they were suitable. We considered the
presence of brownish areas (BAs) in evaluation with NBI to
be fundamental, regardless of the magnification findings. In
cases of Lugol chromoendoscopy, lesions measuring 5 mm
or more in size that were not stained by iodine were con-
sidered fundamental, regardless of pink-color sign.
The criteria that could be used for lesions to be sub-
jected to histopathological evaluation were the positive
results using Lugol chromoendoscopy and/or NBI, or
the positivity of only Lugol chromoendoscopy. Evident
lesions of the esophagus (in other words, lesions that
were easily identified by any method) were either con-
sidered or not considered for calculation in the meta-
analysis depending on whether they were excluded by
the author of the study in question.
Risk of bias in individual studies
The quality of the studies included in the meta-analysis
was assessed by two independent reviewers based on the
pre-defined criteria and discussed with the entire group.
We used the revised version of the Quality Assessment
of Diagnostic Accuracy Studies (QUADAS-2) as a tool
in this process. The QUADAS-2 criteria were used to
assess the risks of biases and applicability in patient se-
lection, in the methods in which the esophageal chro-
moscopies were conducted and interpreted, the way in
which the lesions were classified using anatomical path-
ology, and their clinical significance. The risk of bias in
the flow and time interval in which the tests were per-
formed was also assessed.
The risk of bias in patient selection was also considered,
and case-control or retrospective studies were excluded
beforehand. We considered prospective and randomized
studies with homogeneity between the two groups to be
suitable, as well as cross-sectional studies in which both
methods were evaluated in the same patient. Studies that
excluded subtle lesions that were difficult to identify were
considered inadequate with high risk of bias. Applicability
was considered low when the selected patients were not at
high risk for squamous cell carcinoma of the esophagus or
when diagnosis of the disease had already been established
without being previously cured.
When the endoscopist knew the pathology results of
the recent esophageal biopsy or Lugol chromoendoscopy
before conducting NBI, the study was considered to be
unsuitable in the risk of bias assessment in the index test.
With respect to the applicability of the methods, we evalu-
ated whether a standardization of a well-established, suit-
able criteria was used to consider a lesion positive. For a
lesion to be considered positive in NBI, BAs between the
criteria were necessary. In Lugol chromoendoscopy the
negative-iodine area was required to be greater than or
equal to 5 mm.
With regard to the risk of bias and the applicability of
the gold standard test, the pathologist had to be blinded
to the method that was positive, showing the lesion and
permitting its biopsy. Studies which considered low-
grade dysplasias to be true positives, which provided
sufficient data to distinguish them from high-grade dys-
plasia and squamous cell carcinomas, were included in
the meta-analysis, and this separation was made in the
calculations. These studies were considered to be at in-
creased risk for biases and to have low applicability,
since they did not differentiate lesions requiring inter-
vention from those requiring monitoring.
To assess the risk of biases in flow and time, we con-
sidered cross-sectional studies in which NBI and Lugol
chromoendoscopy were performed sequentially in the
same procedure to be suitable. In prospective studies,
patients needed to be randomized to one of the
groups, and the tests needed to be carried out at the
same time using similar imaging technology. Following
the QUADAS-2, we assessed whether the gold stand-
ard of histopathology was performed in all patients
and whether histopathological evaluation was applied
to all of the lesions identified, whether by Lugol chro-
moendoscopy or only by NBI. We also determined
whether all patients were included in the analysis.
Summary measures and planned methods of analysis
In the meta-analysis, we calculated and showed sensitivity,
specificity, and positive and negative likelihood values in
forest plots. We also created summary receiver operating
characteristic (sROC) curves and estimates of the areas
under the curves. All of these variables were subjected to
per-patient and per-lesion analyses. I-square was used to
evaluate heterogeneity. Due to the high heterogeneity
among the studies, the Dersimonian Laird random effects
model was used for calculation. The sROC curves were
created using the Moses-Littenberg linear model.
Meta-DiSc version 1.4 software was used (Unit of Clinical
Biostatistics, Ramo e Cajal Hospital, Madrid, Spain).
Results
Study selection
In the searches conducted in the PubMed/Medline,
LILACS, Cochrane CENTRAL, Scopus, and Cinahl da-
tabases, 7079 articles were identified. Of these, 7052
were excluded after evaluation of the title and abstract
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showed they were not related to the topic under study.
Of the remaining 27 studies, seven were excluded for
not using Lugol’s iodine solution in comparison with
NBI [9–15] and one was excluded because it did not
permit the diagnostic accuracy of the methods to be
assessed. In this study, 25 endoscopists used a scale to
assess the ease of identifying lesions in photos in each
method [16].
The 19 remaining articles were assessed in full. One of
these, in which the objective was to compare the toler-
ability of NBI to that of Lugol chromoendoscopy, was
excluded because no patients with esophageal squamous
cell carcinoma were evaluated using NBI [17].
Eighteen studies were included in the systematic re-
view, but six were not included in the meta-analysis for
the following reasons: Two studies considered low-grade
dysplasias to be true positives, and it was not possible to
separate and analyze the data from these studies, which
consider them to be false positives [18, 19]. Two did not
provide complete data to calculate sensitivity, specificity,
and accuracy values in either the per-patient or per-
lesion analysis [7, 20]. In one, the examinations were
performed by inexperienced endoscopists [8]; and in an-
other, the data were collected retrospectively [21].
The quantitative analysis was performed in twelve
studies [22–33].
Study characteristics
The twelve studies considered in the meta-analysis pro-
vided all the data necessary to compare the diagnostic
accuracy of NBI and Lugol chromoendoscopy, whether
in a per-patient or a per-lesion analysis, for a total of
1911 patients (Table 1). Of these, eleven studies were
cross-sectional, and one was a prospective, randomized,
controlled study. In the cross-sectional studies, both
NBI and Lugol chromoendoscopy were performed se-
quentially in all patients-first NBI followed by Lugol
chromoendoscopy in the same examination. In the ran-
domized prospective study, the patients were separated
into two homogeneous groups and each group was
assessed using only one of the methods; the author com-
pared the pink-color sign in iodine-negative areas of
Lugol chromoendoscopy to capillary changes in the BAs
in NBI [22].
The criteria for inclusion of the articles selected for
the meta-analysis varied. Ten studies evaluated a high-
risk population; of these, nine included patients with a
history of squamous cell carcinoma of the head and neck
region or the esophagus [22–25, 28–30, 32], one in-
cluded patients with achalasia [26], and one did not
specify [33]. One study evaluated the methods in pa-
tients who already had a diagnosis of pre-malignant le-
sions or squamous cell carcinoma of the esophagus [31].
The other study evaluated the methods in the general
population [27].
The gold standard for all the studies was histo-
pathological assessment of the lesions, but this ana-
lysis was only possible when at least one of the
methods found any suspicious lesions. Patients with-
out suspicious lesions as determined by the two
methods were not subjected to histopathological
evaluation and were considered true negatives. The
criteria for obtaining the material for histopatho-
logical analysis also varied between the studies: any
Table 1 Studies characteristics
Study Patients included
in the analysis
Gold standard Interval Study design Study inclusion criteria Tests methods
Goda 2015 294 Histology Two different groups Prospective randomized HNSCC/ESCC previous
endoscopic resection
NBI x Lugol
Nagami 2014 202 Histology Sequential approach Cross-sectional HNSCC/ESCC previous
endoscopic resection
NBI x Lugol
Takahashi 2014 285 Histology Sequential approach Cross-sectional HNSCC/ESCC NBI x Lugol
Wang 2014 500 Histology Sequential approach Cross-sectional HNSCC NBI x Lugol
Ide 2013 43 Histology Sequential approach Cross-sectional Achalasia NBI x Lugol
Kawai 2012 103 Histology Sequential approach Cross-sectional General population NBI x Lugol
Ide 2011 129 Histology Sequential approach Cross-sectional HNSCC NBI x Lugol
Lecleire2011 30 Histology Sequential approach Cross-sectional Cured ESCC without
esophagectomy
NBI x Lugol
Takenaka 2009 142 Histology Sequential approach Cross-sectional HNSCC NBI x Lugol
Huang 2009 90 Histology Sequential approach Cross-sectional Early ESCC or precancerous NBI x Lugol
Lee 2009 44 Histology Sequential approach Cross-sectional HNSCC NBI x Lugol
Kuraoka 2009 49 Histology Sequential approach Cross-sectional High risk patient for ESCC NBI x Lugol
Total 1911
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Morita et al. BMC Cancer  (2017) 17:54 Page 7 of 14
iodine-negative area and/or BAs, iodine-negative
areas greater than or equal to 5 mm in size and/or
BAs, or only iodine-negative areas greater than
5 mm. In these studies, BAs that stained with
Lugol’s solution or Lugol voiding lesions smaller
than 5 mm were not subjected to histopathological
analysis were considered disease-free. No study con-
ducted random biopsies on patients without suspi-
cious areas.
The criteria to consider a lesion suspicious using NBI
and Lugol chromoendoscopy were not consistent among
the studies. All of the studies and the inclusion criteria
of this review included BAs in NBI among the findings,
whether they were associated with capillary changes or
not. In Lugol chromoendoscopy, iodine-negative areas
greater than or equal to 5 mm were included, regardless
of pink-color sign.
Risk of bias within studies (Table 2)
In assessing risk of bias in patient selection, we found
that nine studies (75%) presented low risk and that the
other three (25%) presented moderate risk. The risk
index test was low in ten studies (83%) and moderate in
two (17%). With regard to the gold standard, nine (75%)
exhibited low risk; two (17%), high risk; and one (8%),
undetermined. Flow and time risk was low in four stud-
ies (33%), moderate in six (50%), and high in two (17%).
The applicability of patient selection was high in ten
studies (83%) and low in two (17%). The index test was
high in nine studies (75%), low in two (17%), and un-
determined in one (8%). The gold standard was high in
nine studies (75%), low in two (17%), and undetermined
in one (8%).
Results of individual studies and Syntheses of results (see
NBI and Lugol graphs)
In the per-patient analysis, eight studies (1123 patients)
were analyzed. Of these, high-grade dysplasia or squa-
mous cell carcinoma of the esophagus was diagnosed in
149 patients (13.26%). Sensitivity of Lugol chromoendo-
scopy was 92% (95% confidence interval (CI), 86 to 96%
and heterogeneity, 50.1%) (Fig. 1). Sensitivity of NBI was
88% (95% CI, 86 to 93% and heterogeneity, 43%) (Fig. 2),
and there was no significant difference between the
methods. Specificity of Lugol chromoendoscopy was
82% (95% CI, 80 to 85% and heterogeneity, 91.8%)
(Fig. 3). Specificity of NBI was 88% (95% CI, 86 to 90%
and heterogeneity, 89.7%) (Fig. 4). These results dem-
onstrate that NBI specificity is significantly superior
to that of Lugol chromoendoscopy. Positive likelihood
ratio for Lugol chromoendoscopy was 5.42 (95% CI,
3.21 to 9.13 and heterogeneity, 89.6%) (Fig. 5) and for
NBI was 8.32 (95% CI, 4.42 to 15.66 and heterogen-
eity, 89.2%) (Fig. 6); there was no statistically signifi-
Fig. 3 Forest plot: Lugol chromoendoscopy’s specificity
per-patient analysis
Fig. 1 Forest plot: Lugol chromoendoscopy’s sensitivity
per-patient analysis
Fig. 4 Forest plot: NBI’s specificity per-patient analysisFig. 2 Forest plot: NBI’s sensitivity per-patient analysis
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cant difference between the methods. Negative likeli-
hood ratio for Lugol chromoendoscopy was 0.13 (95%
CI, 0.08 to 0.23 and heterogeneity, 5.7%) (Fig. 7) and
for NBI was 0.16 (95% CI, 0.11 to 0.24 and hetero-
geneity, 0%) (Fig. 8), and there was no statistically
significant difference between the methods. The post-
test probability of Lugol chromoendoscopy in the
studied population was 0.44; the probability of NBI
was 0.54. The area under the sROC curve for Lugol
chromoendoscopy was 0.9559 (Fig. 9); for NBI, this
value was 0.9611 (Fig. 10).
The per-lesion analysis considered nine articles
with a total of 746 lesions. Of these, 206 (27.61%)
were high-grade dysplasias or squamous cell carcin-
omas of the esophagus. Sensitivity of Lugol chro-
moendoscopy was 98% (95% CI, 95 to 99% and
heterogeneity, 3.3%) (Fig. 11). NBI sensitivity was
94%, (95% CI, 90 to 97% and heterogeneity, 0%)
(Fig. 12), and there was no statistically significant
difference between the methods. Specificity of Lugol
chromoendoscopy was 37%, (95% CI, 33 to 41% and
heterogeneity, 97.5%) (Fig. 13). NBI specificity was
65%, (95% CI, 60 to 69% and heterogeneity, 91.5%)
(Fig. 14). These results demonstrate that NBI specifi-
city is superior to that of Lugol chromoendoscopy,
with statistical significance. Positive likelihood ratio
for Lugol chromoendoscopy was 1.4, (95% CI, 0.79
to 2.51 and heterogeneity, 99.1%) (Fig. 15). In the
case of NBI, this value was 2.62 (95% CI, 1.56 to
4.41 and heterogeneity, 93.1%) (Fig. 16), and there
was no statistically significant difference between the
methods. Negative likelihood ratio for Lugol chro-
moendoscopy was 0.39, (95% CI, 0.09 to 1.71 and
heterogeneity, 62.8%) (Fig. 17) and for NBI was 0.12
(95% CI, 0.07 to 0.21 and heterogeneity, 0%) (Fig. 18),
and there was no statistically significant difference
between the methods. The post-test probability of
Lugol chromoendoscopy for the lesions identified in
the studied population was 0.37, while the same
probability of NBI was 0.50. The area under the
sROC curve in the case of Lugol chromoendoscopy
was 0.9685 (Fig. 19); in the case of NBI, this value
was 0.9587 (Fig. 20).
Discussion
Summary of evidence
Considering the need to identify subtle changes in
the esophageal mucosa for the diagnosis of squa-
mous cell carcinoma in early stages with healing
potential, various methods are being studied. Trad-
itionally, esophageal chromoscopy with Lugol’s iodine
solution is used in high-risk patients to increase the
rate of detection for these lesions relative to white
Fig. 5 Forest plot: Lugol chromoendoscopy’s positive likelihood ratio
per-patient analysis
Fig. 6 Forest plot: NBI’s positive likelihood ratio per-patient analysis Fig. 8 Forest plot: NBI’s negative likelihood ratio per-patient analysis
Fig. 7 Forest plot: Lugol chromoendoscopy’s negative likelihood
ratio per-patient analysis
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light esophagoscopy [5, 6]. Because of the risks of
complications inherent to the use of this dye and be-
cause its application is not practical, other methods
have been developed and compared. One of these
methods is NBI, which is desirable because of its
convenience and because it eliminates the risks in-
herent to the use of Lugol’s solution while providing
comparable diagnostic accuracy.
The meta-analysis conducted in this systematic re-
view showed no statistically significant differences
between the sensitivity of Lugol chromoendoscopy
and that of NBI for diagnosing high-grade dysplasia
and squamous cell carcinoma of the esophagus in a
per-patient or per-lesion analysis. These sensitivities
were as follows: Lugol chromoendoscopy per-patient
and per-lesion: 92 and 88%, respectively, and NBI
per-patient and per-lesion: 98 and 94%, respectively.
Most of the published papers came to the same
conclusion, except for two [18, 19]. These two in-
cluded low-grade dysplasia in the true positives, a
finding that was regarded as a methodological error
in this review and consequently excluded from the
meta-analysis.
As the articles showed, specificities of NBI were super-
ior to those of Lugol chromoendoscopy with statistical
significance, both in per-patient and a per-lesion ana-
lysis. These specificities were as follows: NBI per-patient
and per-lesion: 88 and 82%, respectively, and Lugol
chromoendoscopy per-patient and per-lesion: 65 and
37%, respectively.
Fig. 9 Summary receiver operating characteristic (sROC) curve for
Lugol chromoendoscopy in per-patient analysis
Fig. 10 Summary receiver operating characteristic (sROC) curve for
NBI in per-patient analysis
Fig. 11 Forest plot: Lugol chromoendoscopy’s sensitivity
per-lesion analysis
Fig. 12 Forest plot: NBI’s sensitivity per-lesion analysis
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Considering the calculations of this meta-analysis,
the positive and negative likelihood values for Lugol
chromoendoscopy in per-lesion analysis failed to
obtain statistical significance. This is because its CI
includes the number 1, which corresponds to the
neutral number.
In the per-patient analysis, the positive likelihood
value of Lugol chromoendoscopy was 5.42. This
finding demonstrates that Lugol chromoendoscopy
on a suspicious area increased the 13.26% risk in the
studied population to 45%. The positive likelihood
value for NBI was 8.32, increasing the risk of this
population to 56% when the test was positive. There
was no statistically significant difference between the
methods. Similarly, the post-test probability calcula-
tion showed that the risk of high-grade dysplasia or
squamous cell carcinoma of the esophagus in pa-
tients with suspicious areas detected in Lugol chro-
moendoscopy in this population was 44%, while in
chromoendoscopy with NBI, this risk was 54%. The
negative likelihood value of Lugol chromoendoscopy
was 0.13, indicating that patients without suspicious
lesions in Lugol chromoendoscopy have their initial
disease risk reduced to 1.9%. The value for negative
likelihood for NBI was 0.16, taking initial risk reduc-
tion to 2.3%. There was no statistically significant
difference between the methods.
In the per-lesion analysis, the positive and negative
likelihood values for Lugol chromoendoscopy were
2.62 and 0.12, respectively. This finding demonstrated
that for each positive lesion in NBI, the initial risk of
27.61% for lesions in general rises to 50%, and for
each negative lesion, this risk drops to 4%. The post-
test probability calculation showed that the risk of
high-grade dysplasia or squamous cell carcinoma for
suspicious areas in Lugol chromoendoscopy in this
population was 37%, while in chromoendoscopy with
NBI, this risk was 50%.
The areas under the sROC curve in the per-patient
analysis were 0.9559 for Lugol chromoendoscopy and
0.9611 for NBI, demonstrating good accuracy of the
methods with no significant difference between them. In
the per-lesion analysis, these areas were 0.9685 for Lugol
chromoendoscopy and 0.9587 for NBI. However, the CI
in the sROC curve for Lugol chromoendoscopy was
found to be very extensive, a finding that suggests low
credibility. NBI also demonstrated good accuracy in the
per-lesion analysis.
Limitations
The fact that there is no gold standard applicable to
all patients is a limitation of the articles included in
this systematic review, as is the fact that endoscopy is
an operator-dependent examination. Histopathological
Fig. 13 Forest plot: Lugol chromoendoscopy’s specificity
per-lesion analysis
Fig. 15 Forest plot: Lugol chromoendoscopy’s positive likelihood
ratio per-lesion analysis
Fig. 14 Forest plot: NBI’s specificity per-lesion analysis Fig. 16 Forest plot: NBI’s positive likelihood ratio per-lesion analysis
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evaluation depended on the identification of lesions
by NBI or Lugol chromoendoscopy. In this context,
patients without suspicious lesions identified by either
method were considered not to have the illness and
were there not evaluated using the gold standard. The
criteria for histopathological examination of suspicious
lesions varied between the studies; some regarded the
sensitivity of Lugol chromoendoscopy as being so
high that patients without suspicious lesions in Lugol
chromoendoscopy were considered not to have the
disease regardless of the NBI findings, even without
histopathological evaluation.
In general, the methodology of the studies favored
the sensitivity of Lugol chromoendoscopy if it was
performed by the same endoscopist shortly after
esophageal evaluation with NBI. Additionally, the arti-
cles that did not submit lesions that were positive
NBI but not suspicious in Lugol chromoendoscopy to
the gold standard began with 100% sensitivity for
Lugol chromoendoscopy.
Conclusions
According to both forms of analysis, NBI presented
the same rate of detection of high-grade dysplasia
and esophageal squamous cell carcinoma when com-
pared to Lugol. Regarding the differentiation of high-
grade dysplasia and squamous cell carcinoma from
other esophageal mucosa alterations, NBI was shown
to be superior to Lugol. Thus, we can conclude that
NBI was adequate in evaluating the esophagus in
order to diagnose high-grade dysplasia and squamous
cell carcinoma.
Fig. 17 Forest plot: Lugol chromoendoscopy’s negative likelihood
ratio per-lesion analysis
Fig. 18 Forest plot: NBI’s negative likelihood ratio per-lesion analysis
Fig. 19 Summary receiver operating characteristic (sROC) curve for
Lugol chromoendoscopy in per-lesion analysis
Fig. 20 Summary receiver operating characteristic (sROC) curve for
NBI in per-lesion analysis
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